Global Emerging Therapeutics for Hematological Malignancies Market 2022 - Industry Briefing
This industry report offers market estimates of the global market, followed by a detailed analysis of the type, indication, and region. The global market data on emerging therapeutics for hematological malignancies can be segmented by type: CAR T-cell therapies, monoclonal antibodies. The monoclonal antibodies segment was the largest contributor to the global emerging therapeutics for hematological malignancies market in 2021. Emerging therapeutics for hematological malignancies market is further segmented by indication: leukemia, lymphoma, multiple myeloma. Based on region, the emerging therapeutics for hematological malignancies market is segmented into: Asia Pacific, Europe, North America, Rest of the World (RoW).
The CAR T-cell therapies market is further segmented into tisagenlecleucel (Kymriah), axicabtagene ciloleucel (Yescarta), brexucabtagene autoleucel (Tecartus), others. Furthermore, the monoclonal antibodies market has been categorized into blinatumomab (Blincyto), brentuximab vedotin (Adcetris), daratumumab (Darzalex), inotuzumab ozogamicin (Besponsa), obinutuzumab (Gazyva), sintilimab (Tyvyt), others.
The global emerging therapeutics for hematological malignancies market is highly competitive. Top players covered in Global Emerging Therapeutics for Hematological Malignancies Market Study are AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company (BMS), F. Hoffmann-La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Immune-Onc Therapeutics Inc., Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive market assessment across the major geographies, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
- Get a detailed picture of the Global Emerging Therapeutics for Hematological Malignancies Market
- Identify segments/areas to invest in over the forecast period in the Global Emerging Therapeutics for Hematological Malignancies Market
- Understand the competitive environment, the markets leading players
- The market estimate for ease of analysis across scenarios in Excel format.
- Strategy consulting and research support for three months.
- Print authentication provided for the single-user license.
Part 2. Introduction
Study period
Geographical scope
Market segmentation
Part 3. Emerging therapeutics for hematological malignancies market overview
Part 4. Market breakdown by type
CAR T-cell therapies
Monoclonal antibodies
Part 5. Market breakdown by indication
Leukemia
Lymphoma
Multiple myeloma
Part 6. Market breakdown by region
Asia Pacific
Europe
North America
Rest of the World (RoW)
Part 7. Key companies
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Company (BMS)
F. Hoffmann-La Roche AG
Gilead Sciences, Inc.
GlaxoSmithKline plc
Immune-Onc Therapeutics, Inc.
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited
Part 8. Methodology
Global Coagulation Market Analysis
2022 Global Coagulation Market AnalysisLeading and Emerging Supplier Sales, Shares and Instrument Installed Base by Geographic Region This new report from provides granular data and analysis not available from
USD 4500 View ReportGlobal Breast Cancer Diagnostics Market
This new 7-country report from is available by country, market segment, section, individual marker, and can be customized to specific information needs and budget.This report is designed to assist
USD 5500 View ReportGlobal Emerging Technology Trends Survey 2020 - Thematic Research
Global Emerging Technology Trends Survey 2020 - Thematic ResearchThis survey was designed to help us understand the current attitudes of business leaders towards emerging technologies and evaluate how these attitudes
USD 1950 View ReportGlobal Emerging Gene Therapies Market Research Report 2019-2023
Emerging Gene Therapies Trends within the Technological, Clinical, Regulatory and Competitive Landscape Genomic surgery is increasingly a reality. In the context of China-US trade war and global economic volatility
USD 2850 View ReportFill The Form For Sample Request